$ATOS SEC Filings

Filed On	Filing
09 Oct 2026	8-K: Entry into a Material Definitive Agreement; Material Modifications to Rights of Security Holders +1 more This STAPLED CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of October 8, 2026, is entered into by and between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limi...
29 Sep 2026	8-K: Other Events Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
18 Sep 2026	8-K: Regulation FD Disclosure Advancing (Z)-Endoxifen A potential best-in-class oral SERM/SERD for estrogen-driven diseases NASDAQ: ATOS www.atossatherapeutics.com Seattle, Washington Corporate & Investor Presentation September 2026 Exhibit 99.1
07 Aug 2026	10-Q
07 Aug 2026	8-K: Results of Operations and Financial Condition
12 Jun 2026	424B5
11 Jun 2026	8-K: Entry into a Material Definitive Agreement
14 May 2026	Form 4: Steinhart Richard I, Director Received 10,000 shares as a grant or award
14 May 2026	Form 4: Chen Shu-Chih, Director Received 10,000 shares as a grant or award
14 May 2026	Form 4: Remmel H. Lawrence, Director Received 10,000 shares as a grant or award
14 May 2026	Form 4: Finn Jonathan, Director Received 10,000 shares as a grant or award
14 May 2026	Form 4: Galli Stephen J, Director Received 10,000 shares as a grant or award
14 May 2026	Form 4: Cigler Tessa, Director Received 10,000 shares as a grant or award
08 May 2026	8-K: Financial Statements and Exhibits
08 May 2026	10-Q
08 May 2026	8-K: Submission of Matters to a Vote of Security Holders
16 Apr 2026	8-K: Other Events
31 Mar 2026	Form 4: Quay Steven C, Director Received 65,000 shares as a grant or award
30 Mar 2026	Form 4: Daniel Mark James, Chief Financial Officer Received 63,000 shares as a grant or award
30 Mar 2026	ARS

Comments